Related Experiment Video
Updated: Jan 16, 2026
Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
Published on: September 20, 2020
Comprehensive Review of Transarterial Chemoembolization Plus Systemic Therapy in Advanced Hepatocellular Carcinoma
Arif Akyildiz1, Betul Gok Yavuz2, Rashad Ismayilov3
1Department of Medical Oncology, Hacettepe University Medical School, Ankara, Turkey.
Introduction:
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the fifth most common cancer worldwide. For patients with unresectable, localized, intermediate-stage HCC, the standard treatment is transarterial chemoembolization (TACE).
Methods:
Given the recent advances in systemic treatments for HCC with immunotherapy and targeted therapies, several studies have explored the potential benefits of combining TACE with systemic therapy, owing to the possible synergistic effects. This review analyzes recent clinical studies of patients with unresectable HCC who received TACE in combination with different classes of systemic therapies.
Conclusion:
Collectively, these studies suggest that combining TACE with systemic therapy may enhance treatment response and improve survival outcomes.
More Related Videos
09:49Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
Published on: December 2, 2013
09:11Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...